Opus Genetics Inc. (IRD)
Opus Genetics Statistics
Share Statistics
Opus Genetics has 47.18M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 47.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 5,266 |
| FTD / Avg. Volume | 2.4% |
Short Selling Information
The latest short interest is 126.99K, so 0.27% of the outstanding shares have been sold short.
| Short Interest | 126.99K |
| Short % of Shares Out | 0.27% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.55 and the forward PE ratio is null. Opus Genetics's PEG ratio is 0.
| PE Ratio | -0.55 |
| Forward PE | n/a |
| PS Ratio | 2.89 |
| Forward PS | n/a |
| PB Ratio | 4.73 |
| P/FCF Ratio | -1.24 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Opus Genetics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.
| Current Ratio | 3.24 |
| Quick Ratio | 3.24 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $610,666.67 |
| Profits Per Employee | $-3,196,222.22 |
| Employee Count | 18 |
| Asset Turnover | 0.3 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -95.12% in the last 52 weeks. The beta is 0.27, so Opus Genetics's price volatility has been higher than the market average.
| Beta | 0.27 |
| 52-Week Price Change | -95.12% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 56.58 |
| Average Volume (20 Days) | 219,454 |
Income Statement
In the last 12 months, Opus Genetics had revenue of 10.99M and earned -57.53M in profits. Earnings per share was -2.15.
| Revenue | 10.99M |
| Gross Profit | 10.99M |
| Operating Income | -62.07M |
| Net Income | -57.53M |
| EBITDA | -57.52M |
| EBIT | -57.53M |
| Earnings Per Share (EPS) | -2.15 |
Balance Sheet
The company has 30.32M in cash and 0 in debt, giving a net cash position of 30.32M.
| Cash & Cash Equivalents | 30.32M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -139M |
| Total Assets | 36.86M |
| Working Capital | 25.32M |
Cash Flow
In the last 12 months, operating cash flow was -25.58M and capital expenditures 0, giving a free cash flow of -25.58M.
| Operating Cash Flow | -25.58M |
| Capital Expenditures | n/a |
| Free Cash Flow | -25.58M |
| FCF Per Share | -0.96 |
Margins
Gross margin is 100%, with operating and profit margins of -564.72% and -523.4%.
| Gross Margin | 100% |
| Operating Margin | -564.72% |
| Pretax Margin | -523.4% |
| Profit Margin | -523.4% |
| EBITDA Margin | -523.31% |
| EBIT Margin | -564.72% |
| FCF Margin | -232.68% |
Dividends & Yields
IRD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IRD is $7, which is 644.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 644.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Nov 6, 2020. It was a backward split with a ratio of 1:4.
| Last Split Date | Nov 6, 2020 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | -8.6 |
| Piotroski F-Score | 1 |